

Study ID	N	Mean age (SD)	Female (%)	Past psychedelic use (%)	Primary patient diagnosis	Intervention	Control	Study Endpoint
<i>Main meta-analysis</i>								
Ross 2016	31	56 (13)	62	55	Advanced cancer	Single dose psilocybin (0.3 mg/kg)	Single dose niacin (250 mg)	7 weeks
Griffiths 2016	56	56.3 (10.5)	49	45	Advanced cancer	Single high dose psilocybin (22 or 30 mg/70kg)	Single low dose psilocybin (1 or 3 mg/70kg)	5 weeks
Davis 2021	27	39.8 (12.2)	67	25	MDD	Two doses psilocybin (20 mg/70kg; 30 mg/70kg)	Waitlist	4 weeks
Goodwin 2022	158*	39.8 (12.1)	52	6	TRD	Single high dose psilocybin (25 mg)	Single low dose psilocybin (1 mg)	3 weeks
von Rotz 2023	52	36.8 (10.4)	37	31	MDD	Single dose psilocybin (0.215 mg/kg)	Single dose placebo (mannitol)	2 weeks
Raison 2023	104	41.1 (11.3)	50	24	MDD	Single dose psilocybin (25 mg)	Single dose niacin (100 mg)	6 weeks
Rosenblat 2024	31	44.4 (13.7)	39	19	TRD	Single dose psilocybin (25 mg)	Waitlist	2 weeks
Back 2024	30	38 (n/a)	50	7	MDD	Single dose psilocybin (25 mg)	Single dose niacin (100 mg)	4 weeks
Rieser 2025	40	37.2 (11.9)	38	51	AUD	Single dose psilocybin (25 mg)	Single dose placebo (mannitol)	4 weeks
<b>Total N (main)</b>	<b>604</b>	-	-	-	-	-	-	-
<b>Mean (main)</b>	<b>67</b>	<b>42.1</b>	<b>50</b>	<b>22</b>	-	-	-	<b>3.9 weeks</b>
<i>Expanded meta-analysis</i>								
Grob 2011	12	36-58 (n/a)	92	67	Advanced cancer	Single dose psilocybin (0.2 mg/kg)	Single dose niacin (250 mg)	2 weeks
Carhart-Harris 2021	59	41 (n/a)	34	27	MDD	Two doses psilocybin (25 mg) three weeks apart	Daily escitalopram (10-20 mg) for 6 weeks	3 weeks
Krempien 2023	18*	NA	NA	NA	MDD	Single dose deuterated psilocybin derivative (16 mg)	Single dose placebo (unknown)	3 weeks
<b>Total N (overall)</b>	<b>107</b>	-	-	-	-	-	-	-
<b>Mean (overall)*</b>	<b>36</b>	<b>42.0</b>	<b>44</b>	<b>34</b>	-	-	-	<b>4.5 weeks</b>

Table 1: Summary of RCTs on psilocybin for depressive symptoms. \*N for these studies reflect the number of participants in the high and low dose groups. Goodwin 2022 and Krempien 2023 contained 75 and 18 participants in the medium dose arms, respectively. These arms are included in the database, but not used in the present analyses with the exception of the Goodwin 2022 medium dose arm in the alternate dosing for Goodwin et al. sensitivity analysis. Study endpoints are the reported primary endpoints for each study and given in weeks since the final dose. MDD = major depressive disorder; TRD = treatment-resistant depression; AUD = alcohol use disorder.